BGLC

BioNexus Gene Lab Corp Common stock (BGLC)

Stock · NASDAQ · Health Care

$1.22as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 3, 2026

BGLC Included in 12 Industrial Stocks Moving After-Market Wednesday. BGLC was among the 12 industrial stocks that moved in the after‑market session on Wednesday. The move reflects after‑hours trading activity for the sector. The stock remains in a range that has seen moderate volatility, with an RSI of 37 and a support level near $1.98.

Active signals

High Beta46.9%
200 SMA Touch0.0%
Resistance level
$2.01
Industry
Medical Specialities

What BGLC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Bollinger Band Breakdown26-4.3%42%
Volume Spike21-9.2%24%
Bollinger Band Breakout14-30.4%21%
Any 20-session window (baseline)-7.5%32%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About BGLC

BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment H…

Sector
Health Care
Industry
Medical Specialities
Employees
19

Fundamentals

1-day range
$1.2$1.24
Market cap
$3.82M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
$-1.25
Dividend yield
—
Beta
1.96
Avg. volume
11.0K
52-week range
$1.07$5.89

How BioNexus Gene Lab Corp Common stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$7.42MCost of Revenue$6.34M (85%)SG&A$3.27M (44%)R&D$50.7K (1%)BGLC

Source: 10-K filed Apr 14, 2026 · via SEC EDGAR / Finnhub

Gross Profit$1.09M(15%)
Operating Income-$2.97M(-40%)

BioNexus Gene Lab Corp Common stock Competitors

Chosen by industry and closest market cap.

  • BGLC
    BioNexus Gene Lab Corp Common stock
    $1.2
    ▼ 1.64%
    Market cap $3.82MP/E —
    $1.07$5.89
  • ACON
    Aclarion Inc. Common Stock
    $1.85
    ▼ 5.27%
    Market cap $5.79MP/E —
    $1.89$9.38
  • AMS
    American Shared Hospital Services Common Stock
    $1.28
    ▲ 1.59%
    Market cap $9.67MP/E —
    $1.21$2.39
  • ADVB
    Advanced Biomed Inc. Common Stock
    $3.98
    ▼ 18.44%
    Market cap $12.29MP/E 1.53
    $3.61$24.23
  • YDESW
    YD Bio Limited Warrants
    $0.599
    ▼ 9.24%
    Market cap $16.29MP/E —
    $0.1904$2.5
  • MDXH
    MDxHealth SA Ordinary Shares
    $0.207
    ▼ 65.73%
    Market cap $22.50MP/E —
    $0.4$5.33
  • SERA
    Sera Prognostics Inc. Class A Common Stock
    $2.06
    ▲ 1.48%
    Market cap $78.32MP/E —
    $1.56$3.95

P/E shows — for peers not currently carrying a live signal of their own.

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.